Vayuna Therapeutics
ADCs and Parenteral Formulations with V-001for PIK3CA-Mutated and
Treatment-Resistant Cancers
Limited effective therapies for treatment-resistant solid tumors.
PIK3CA mutations drive resistance in ~40% of HR+ breast cancers leading to excessive PI3K signaling activation and treatment resistance.
Existing treatments are imprecise, resulting in suboptimal outcomes and significant toxicity.
V-001 outperforms standards of care in NCI-60 screen, targeting PIK3CA-mutated and resistant cancers
Precision delivery of V-001 payload for enhanced therapeutic effect.
Systemic treatment for advanced & metastatic PIK3CA-mutated cancers.
Precision targeting for better outcomes, reduced toxicity and personalized care.
Please enable JavaScript in your browser to view the content